Additional Advances in Relapsed/Refractory Multiple Myeloma Research and Clinical Trials With Rahul Banerjee, MD, FACP

The fight against relapsed/refractory multiple myeloma is evolving rapidly, with groundbreaking research and clinical trials paving the way for innovative treatments. But as new therapies emerge, addressing healthcare disparities and improving access to these life-changing advancements has never been more critical. In this episode, Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center and co-chair of i3 Health’s Multiple Myeloma Task Force activity, shares his expert perspective on the latest developments in CAR T-cell therapy and bispecific antibodies. He also highlights ongoing efforts to make these cutting-edge treatments more practical and accessible for patients, ensuring no one is left behind in the fight against this challenging disease. Don’t miss this engaging discussion packed with actionable insights for healthcare professionals. After listening, take the next step by exploring the full Task Force activity and related resources to deepen your understanding and make a difference in your practice. Click below to access these valuable resources: Accredited CME/NCPD Podcast: bit.ly/3B4gSB1 Position Statement in Blood Cancer Journal: www.nature.com/articles/s41408-024-01129-0 Live Task Force Recording: www.youtube.com/live/TILCPB6w3Ig?…=1Z8m4dA2qwLJd6rN